ABBV News and Press, AbbVie Inc. From 02/10/26

2026-02-10 09:45:12 ET Foreword As supplement to this article, please note that The Motley Fool , which sourced this latest list, and SureDividend both update their lists periodically. Kiplinger also featured this recent selection of Kings.... Read the full art...

2026-02-10 08:30:33 ET Improved efficacy, faster onset, and scalable platforms drive investor interest in next-gen CNS assets New York, NY –February 10, 2026 – Market News Updates News Commentary – Novel serotonergic agonists (“NSAs”...

2026-02-10 05:45:33 ET Introduction Read the full article on Seeking Alpha For further details see: Gilead Sciences: Buy This Stock For Both Dividend And Growth

2026-02-07 16:05:41 ET More on U.S. Markets 20 out of 23 S&P 500 industrial stocks beat EPS estimates this week: Earnings Scorecard Read the full article on Seeking Alpha For further details see: 96 of 123 S&P 500 companies post EPS growth in latest earnings week...

2026-02-07 11:30:50 ET More on Healthcare AbbVie: The Market Is Getting It Wrong AbbVie: Skyrizi And Rinvoq Growth Isn't Everything, But It's A Lot AbbVie: Double-Digit Growth For Immunology Products Continues With HUMIRA Surprise CVS pharmacies accepting Tru...

2026-02-07 08:30:00 ET ... Read the full article on Seeking Alpha For further details see: Big Pharma's Earnings Week: Strong Performance, Obesity Wars, LOE Management And More

2026-02-06 17:59:12 ET Introduction The Dividend Champions list is a monthly compilation of companies which have consistently increased their annual dividend payouts. However, since this list is only produced once per month, the data in it can quickly get out of date. Furthermore, w...

2026-02-05 08:52:07 ET It has been quite a while since I've covered AbbVie Inc. ( ABBV ). Back in August of last year, I initiated coverage with a buy rating as earnings were strong and their Rinvoq had new market potential. While the chart below shows that this bullish call wor...

2026-02-05 04:25:07 ET Two Years of Great Growth It has been two years since I last covered AbbVie ( ABBV ) on Seeking Alpha. At that time, the stock had been stuck in a $130 to $170 range since 2022 on worries about the company's newer immunology drugs, Skyrizi and Rinvoq, ...

2026-02-04 18:04:48 ET The last time I spoke about AbbVie Inc. ( ABBV ) it was in a Seeking Alpha article entitled as " AbbVie: Increased Outlook For 2025 And Expansions Merit Continued 'Strong Buy' Rating ." For this article I had noted a Strong Buy rating on the stock, des...